Brigatinib-5008
Completed
A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
Clinicaltrials.gov
#NCT04887519About this clinical trial
The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC). Treatment with brigatinib and follow-up will be according to routine clinical practice. Study doctors will review the participants' medical records at the start of the study, then at 12 and 24 weeks after treatment starts.
AR
Observational clinical trial.
At a glance
What medical conditions were being studied?
Non-small Cell Lung Cancer (NSCLC)
What was the clinical trial testing?
No Intervention
How many participants were enrolled?
39
Were placebos part of the clinical trial?
No
When was the clinical trial conducted?
Dec 2020 - Mar 2023
How long was participation in the clinical trial?
Participants will be in this study for 24 weeks.
Key requirements
Sex
All
Age
18+ years
Healthy volunteers?
No
Entry criteria
Both men and women can take part
Must be adults 18 years or older.
Must have ALK positive metastatic NSCLC previously treated with crizotinib, or ALK positive metastatic NSCLC not previously treated with an ALK inhibitor.
Additional entry criteria will be discussed with the study doctor.